Scholar Rock(NASDAQ) SRRK

Scholar Rock Holding Corporation makes medicines for rare muscle diseases. These treatments help children regain muscle strength and movement. The company targets proteins that control how muscles grow.

Treatments for Muscle and Growth

• Apitegromab: Investigational antibody designed to increase muscle mass and strength in patients; currently under regulatory review for spinal muscular atrophy.
• SRK-439: Subcutaneous treatment candidate focused on rare and debilitating neuromuscular diseases; currently undergoing Phase 1 clinical trials.
• SRK-181: Potential cancer therapy targeting solid tumors resistant to standard treatments; currently available for strategic partnership opportunities.
• Pipeline Programs: Early-stage research targeting fibrotic diseases and iron-restricted anemias; includes candidates like SRK-373 and SRK-256.

Moving Toward Commercial Launch

• Resubmitted a Biologics License Application to the FDA for apitegromab in March 2026.
• Initiated a Phase 2 study evaluating apitegromab for facioscapulohumeral muscular dystrophy in the second quarter of 2026.
• Entered a financing agreement for up to $350 million with Blue Owl Capital Corporation in February 2026.
• Received validation from the European Medicines Agency for a marketing authorization application in March 2025.

Precision Targeting of Growth Factors

Scholar Rock uses a proprietary platform to target the latent forms of protein growth factors locally and selectively. This approach allows for precise inhibition of proteins like myostatin to treat specific neuromuscular conditions.

Capital and Costs

• Net loss was $215.4 million for the six months ended June 30, 2026, which widened 16.6% year over year.
• Total operating expenses reached $210.9 million for the six-month period ended June 30, 2026.
• Cash, cash equivalents, and marketable securities totaled $492.1 million as of June 30, 2026.
• Accumulated deficit grew to $1.5 billion as of June 30, 2026.

Shifting From Research to Sales

Scholar Rock has transitioned from an early-stage research firm toward a commercial-ready biopharmaceutical company. Its focus on specialized growth factor biology provides a distinct path for addressing rare neuromuscular diseases.